Inflammation modulation and cardiovascular disease prevention
暂无分享,去创建一个
[1] L. Espinoza,et al. Does TNF-alpha blockade play any role in cardiovascular risk among rheumatoid arthritis (RA) patients? , 2009, Clinical Rheumatology.
[2] Robert Dufour,et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. , 2013, The Canadian journal of cardiology.
[3] P. Shah,et al. Immunization using an Apo B-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apo E (-/-) mice. , 2005, Biochemical and biophysical research communications.
[4] F. Martinon,et al. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. , 2002, Molecular cell.
[5] J. Omens,et al. Etanercept or intravenous immunoglobulin attenuates expression of genes involved in post-myocardial infarction remodeling. , 2005, Cardiovascular research.
[6] J. Lekakis,et al. Inhibition of Interleukin-1 by Anakinra Improves Vascular and Left Ventricular Function in Patients With Rheumatoid Arthritis , 2008, Circulation.
[7] F. Wolfe,et al. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. , 2008, Arthritis and rheumatism.
[8] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[9] Jennifer G. Robinson,et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis , 2012, The Lancet.
[10] N. Roehm,et al. Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI. , 1999, The Journal of pharmacology and experimental therapeutics.
[11] H. Mann,et al. Clinical trials roundup in idiopathic inflammatory myopathies , 2011, Current opinion in rheumatology.
[12] S. Yusuf,et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.
[13] R. Winzen,et al. Selective up-regulation of the 75-kDa tumor necrosis factor (TNF) receptor and its mRNA by TNF and IL-1. , 1993, Journal of immunology.
[14] Jennifer G. Robinson,et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[15] Jashin J. Wu,et al. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. , 2013, Journal of drugs in dermatology : JDD.
[16] B. Beutler,et al. Alternative cleavage of the cachectin/tumor necrosis factor propeptide results in a larger, inactive form of secreted protein. , 1989, The Journal of biological chemistry.
[17] C. Turesson,et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. , 2005, The Journal of rheumatology.
[18] J. Gergely,et al. Inhibition of cholesterol atherosclerosis by immunisation with beta-lipoprotein. , 1959, Lancet.
[19] P. Libby,et al. Pathophysiology of Coronary Artery Disease , 2005, Circulation.
[20] G. Moneta,et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .
[21] P. Robbins,et al. Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. , 2000, Circulation.
[22] E. Bruckert,et al. Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects. , 1999, Circulation.
[23] J. Kuiper,et al. Vaccination strategies in atherosclerosis , 2011, Thrombosis and Haemostasis.
[24] I. Roifman,et al. Chronic inflammatory diseases and cardiovascular risk: a systematic review. , 2011, The Canadian journal of cardiology.
[25] Steven Hawken,et al. Preventive cardiologyAbstractsEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study , 2004 .
[26] Robert Dufour,et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial , 2012, The Lancet.
[27] R. Frikke-Schmidt. Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease in the general population. , 2010, Atherosclerosis.
[28] G. Cook,et al. Primer: inflammasomes and interleukin 1β in inflammatory disorders , 2008, Nature Clinical Practice Rheumatology.
[29] A. Golay,et al. IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? , 2002, The Journal of clinical endocrinology and metabolism.
[30] P. Sfikakis,et al. A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. , 2011, Atherosclerosis.
[31] H. Ginsberg. Statins in cardiometabolic disease: what makes pitavastatin different? , 2013, Cardiovascular Diabetology.
[32] Prospective study of inhaled corticosteroid use, cardiovascular mortality, and all-cause mortality in asthmatic women. , 2008, Chest.
[33] A. Takeshita,et al. Interleukin-1 stimulates cytokines, prostaglandin E2 and matrix metalloproteinase-1 production via activation of MAPK/AP-1 and NF-kappaB in human gingival fibroblasts. , 2005, Cytokine.
[34] D. Newby,et al. Cardiovascular effects of tumour necrosis factor α antagonism in patients with acute myocardial infarction: a first in human study , 2013, Heart.
[35] H. Cohen,et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. , 1999, The American journal of medicine.
[36] T. Therneau,et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. , 2007, Arthritis and rheumatism.
[37] R. Pettigrew,et al. Hypercortisolism is associated with increased coronary arterial atherosclerosis: analysis of noninvasive coronary angiography using multidetector computerized tomography. , 2013, The Journal of clinical endocrinology and metabolism.
[38] William Weintraub,et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.
[39] Paul M. Ridker,et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .
[40] A. Hall,et al. Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study) , 2008, Trials.
[41] V. Gross,et al. Inflammatory mediators in chronic inflammatory bowel diseases , 1991, Klinische Wochenschrift.
[42] J. Danesh,et al. Major lipids, apolipoproteins, and risk of vascular disease. , 2009, JAMA.
[43] K. Ascah,et al. Mobile ventricular thrombus arising from the mitral annulus in patients with dense mitral annular calcification. , 2010, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.
[44] Y. Sharabi,et al. Differential role and tissue specificity of interleukin-1alpha gene expression in atherogenesis and lipid metabolism. , 2007, Atherosclerosis.
[45] P. Kiely,et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. , 2010, Rheumatology.
[46] D. Fearon,et al. Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist. , 2008, Circulation.
[47] Wolfgang Koenig,et al. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. , 2013, International journal of cardiology.
[48] D. Grobbee,et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis , 2010, The Lancet.
[49] R. Schleimer,et al. Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids. , 1999, American journal of respiratory cell and molecular biology.
[50] K. Amano,et al. Tocilizumab Monotherapy Reduces Arterial Stiffness as Effectively as Etanercept or Adalimumab Monotherapy in Rheumatoid Arthritis: An Open-label Randomized Controlled Trial , 2011, The Journal of Rheumatology.
[51] D. Mozaffarian,et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. , 2011, The American journal of cardiology.
[52] M. Landray,et al. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment , 2013, European heart journal.
[53] C. Zhang,et al. Interleukin 6 destabilizes atherosclerotic plaques by downregulating prolyl-4-hydroxylase α1 via a mitogen-activated protein kinase and c-Jun pathway. , 2012, Archives of biochemistry and biophysics.
[54] M. Moskowitz,et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase , 2002, Nature Medicine.
[55] G. Biondi-Zoccai,et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). , 2010, The American journal of cardiology.
[56] A. Maguire,et al. Use of oral corticosteroids and the risk of acute myocardial infarction. , 2007, Atherosclerosis.
[57] G. Owens,et al. Interleukin-1β modulates smooth muscle cell phenotype to a distinct inflammatory state relative to PDGF-DD via NF-κB-dependent mechanisms. , 2012, Physiological genomics.
[58] Stephan von Haehling,et al. Inflammatory mediators in chronic heart failure: an overview , 2004, Heart.
[59] HirokazuKirii,et al. Lack of Interleukin-1β Decreases the Severity of Atherosclerosis in ApoE-Deficient Mice , 2003 .
[60] J. Danesh,et al. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies , 2010, The Lancet.
[61] T. Shimokama,et al. Localization of T lymphocytes and macrophages expressing IL-1, IL-2 receptor, IL-6 and TNF in human aortic intima. Role of cell-mediated immunity in human atherogenesis , 2005, Virchows Archiv A.
[62] L. Pasumarthy,et al. Common Pitfalls in Management of Inflammatory Bowel Disease , 2009, Gastroenterology research.
[63] John Spertus,et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.
[64] M. Hochberg,et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis , 2010, Annals of the rheumatic diseases.
[65] E. Fishman,et al. Aortic valve calcification in systemic lupus erythematosus , 2006, Lupus.
[66] S. Yamasaki,et al. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis , 2011, Rheumatology International.
[67] G. Moneta,et al. Major Lipids, Apolipoproteins, and Risk of Vascular Disease , 2010 .
[68] G. Walsh. Canakinumab for the treatment of cryopyrin-associated periodic syndromes. , 2009, Drugs of Today.
[69] C. Holt,et al. Interleukin-1β in Coronary Arteries of Patients With Ischemic Heart Disease , 1996 .
[70] R. Mailhammer,et al. In Activated Mast Cells, IL-1 Up-Regulates the Production of Several Th2-Related Cytokines Including IL-9 , 2000, The Journal of Immunology.
[71] H. Holtmann,et al. Down regulation of the receptors for tumor necrosis factor by interleukin 1 and 4 beta-phorbol-12-myristate-13-acetate. , 1987, Journal of immunology.
[72] A. Takeshita,et al. Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. , 1996, The Journal of clinical investigation.
[73] C. Lewis,et al. Impact of Weight Loss on Ankle-Brachial Index and Inter-Artery Blood Pressures in Overweight and Obese Adults with Diabetes , 2013, Obesity (Silver Spring, Md.).
[74] C. Cooper,et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case–control study , 2004, Heart.
[75] A. Cerami,et al. Characterization of high molecular weight glycosylated forms of murine tumor necrosis factor. , 1990, Biochemical and biophysical research communications.
[76] C. Holt,et al. Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. , 1996, Arteriosclerosis, thrombosis, and vascular biology.
[77] P. Libby,et al. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. , 2013, Immunity.
[78] K. Kalbak. Incidence of arteriosclerosis in patients with rheumatoid arthritis receiving long-term corticosteroid therapy. , 1972, Annals of the rheumatic diseases.
[79] P. Armstrong,et al. Adverse effects of corticosteroids on the cardiovascular system. , 2000, The Canadian journal of cardiology.
[80] J. Pelletier,et al. Cardiovascular adverse effects of anti-inflammatory drugs. , 2013, Anti-inflammatory & anti-allergy agents in medicinal chemistry.
[81] E. Serné,et al. Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis , 2013, Annals of the rheumatic diseases.
[82] Egil Lien,et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals , 2010, Nature.
[83] P. Kovanen,et al. Cholesterol Crystals Activate the NLRP3 Inflammasome in Human Macrophages: A Novel Link between Cholesterol Metabolism and Inflammation , 2010, PloS one.
[84] D. Carroll,et al. The role of inflammation and cardiovascular disease risk on microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional and longitudinal study , 2012, Arthritis Research & Therapy.
[85] Mark Woodward,et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies , 2012 .
[86] P. Kiely,et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. , 2010, Rheumatology.
[87] S. Lewington. Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies (vol 360, pg 1903, 2002) , 2003 .
[88] A. Steensberg,et al. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. , 2003, American journal of physiology. Endocrinology and metabolism.
[89] J. Danesh,et al. Large-scale association analysis identifies new risk loci for coronary artery disease , 2013 .
[90] T. MacDonald,et al. Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease , 2004, Annals of Internal Medicine.